PDF herunterladen
Arzneimittelforschung 2012; 62(08): 360-366
DOI: 10.1055/s-0032-1312601
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Synthesis and Anti-proliferative Activity of Substituted-Anilinoquinazolines and Its Relation to EGFR Inhibition

D. A. A El Ella   *
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
,
K. A. Saleh
2   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Russian Egyptian University, Cairo, Egypt
,
M. Hassan
2   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Russian Egyptian University, Cairo, Egypt
,
N. Hamdy
3   Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
,
M. E. El-Araby
4   Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Helwan University, Helwan, Egypt
,
K.A. M. Abouzid   *
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
› Institutsangaben
Weitere Informationen

Publikationsverlauf

accepted 20. April 2012

received 17. Februar 2012

Publikationsdatum:
21. Juni 2012 (online)

    Lizenzen und Reprints

Abstract

4-Anilinoquinazoline is a privileged scaffold in developing small molecule inhibitors of tyrosine kinases (TK) especially epidermal growth factor receptor (EGFR). 2 series belonging to 3'-substituted-4-anilinoquinazoline scaffold were synthesized and screened in vitro on isolated and a breast cancer cell line. The research aims at exploring the activity of compounds having diverse substituents at 3' position of the aniline moiety. Generally, the meta-substituted-anilinoquinazolines exhibited significant inhibitory activity against isolated enzyme as well as MCF-7 cancer cell line. For instance, compound 10b inhibited >99% of EGFR activities at 10 µM concentration. 6 of the tested compounds exhibited range of anti-proliferative activity below 10 µM potency. In particular, compounds 6e and 10b displayed the highest activity among the tested compounds with IC50 values equal to 8.6 and 4.84 µM, respectively. Structure-based tools were utilized to rationalize EGFR-TK binding of compound 10b since it is the most active compound in the enzyme inhibition test.

Key words

quinazoline - anilinoquinazoline - EGFR inhibitors - tyrosine kinase inhibitors - anti-cancer - structure-based design
* 

* These authors contributed equally to this work.


 

  • References

  • 1 Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-365
    CrossrefPubMedGoogle Scholar
  • 2 Li R, Stafford JA. Kinase Inhibitor Drugs. 1st ed. Hoboken, New Jersey: John Wiley & Sons; 2009
    CrossrefGoogle Scholar
  • 3 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-134
    CrossrefPubMedGoogle Scholar
  • 4 Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006; 5: 2820-2826
    CrossrefPubMedGoogle Scholar
  • 5 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39
    CrossrefPubMedGoogle Scholar
  • 6 Cataldo VD, Gibbons DL, Pérez-Soler R et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011; 364: 947-955
    CrossrefPubMedGoogle Scholar
  • 7 Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-289
    CrossrefPubMedGoogle Scholar
  • 8 Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer – search and destroy. Eur J Cancer 2006; 42: 17-23
    CrossrefPubMedGoogle Scholar
  • 9 Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. Int J Clin Exp Pathol 2011; 4: 403-409
    PubMedGoogle Scholar
  • 10 Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
    CrossrefPubMedGoogle Scholar
  • 11 Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311
    CrossrefPubMedGoogle Scholar
  • 12 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774
    CrossrefPubMedGoogle Scholar
  • 13 Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31: 2332-2348
    CrossrefPubMedGoogle Scholar
  • 14 Cruz-López O, Conejo-García A, Núñez MC et al. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Curr Med Chem 2011; 18: 943-963
    CrossrefPubMedGoogle Scholar
  • 15 Cumming JG, McKenzie CL, Bowden SG et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2004; 14: 5389-5394
    CrossrefPubMedGoogle Scholar
  • 16 Rewcastle GW, Denny WA, Bridges AJ et al. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 1995; 38: 3482-3487
    CrossrefPubMedGoogle Scholar
  • 17 Thompson AM, Bridges AJ, Fry DW et al. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1995; 38: 3780-3788
    CrossrefPubMedGoogle Scholar
  • 18 Abouzid K, Shouman S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg Med Chem 2008; 16: 7543-7551
    CrossrefPubMedGoogle Scholar
  • 19 Kamath S, Buolamwini JK. Targeting EGFRand HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 2006; 26: 569-594
    CrossrefPubMedGoogle Scholar
  • 20 Heindel ND, Brodof TA, Kogelschatz JE. Cyclization of amine-acetylene diester adducts. Modification of the Conrad-Limpach method. J Heterocycl Chem 1966; 3: 222-223
    PubMedGoogle Scholar
  • 21 Althuis TH, Hess HJ. Synthesis and identification of the major metabolites of prazosin formed in dog and rat. J Med Chem 1977; 20: 146-149
    CrossrefPubMedGoogle Scholar
  • 22 Jin Y, Li H-Y, Lin L-P et al. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Bioorg Med Chem 2005; 13: 5613-5622
    CrossrefPubMedGoogle Scholar
  • 23 Tsou H-R, Mamuya N, Johnson BD et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J Med Chem 2001; 44: 2719-2734
    CrossrefPubMedGoogle Scholar
  • 24 Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst 1990; 82: 1107-1112
    CrossrefPubMedGoogle Scholar
  • 25 Konecny GE, Pegram MD, Venkatesan N et al. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Res 2006; 66: 1630-1639
    CrossrefPubMedGoogle Scholar
  • 26 Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-46272
    CrossrefPubMedGoogle Scholar
  • 27 Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-227
    CrossrefPubMedGoogle Scholar
  • 28 Griera R, Armengo M, Reyes A et al. Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists. Eur J Med Chem 1997; 32: 547-570
    CrossrefPubMedGoogle Scholar
  • 29 Brancaccio G, Lettieri G, Viterbo R. Orientation studies in the coumaran series. Revised structure of the nitration product of 5-acetamido-2-methylcoumaran via the elucidation of the Claisen rearrangement of m-acetoamidophenyl allyl ether. Eur J Org Chem 1972; 38: 831-832
    PubMedGoogle Scholar
  • 30 Dietrich SW, Smith RN, Fukunaga JY et al. Dihydrofolate Reductase Inhibition by 2,4-Diaminotriazines: A Structure-Activity Study. Arch biochem biophys 1979; 194: 600-611
    CrossrefPubMedGoogle Scholar